



## Clinical trial results:

### A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta Active-Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy

#### Summary

EudraCT number	2016-003553-15
Trial protocol	LV HU BG
Global end of trial date	18 March 2020

#### Results information

Result version number	v1 (current)
This version publication date	16 February 2024
First version publication date	16 February 2024

#### Trial information

##### Trial identification

Sponsor protocol code	GC-627-05
-----------------------	-----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03252431
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	Evive Biotechnology (Shanghai) Ltd
Sponsor organisation address	Building 2-B, 797 Puxing HWY, Shanghai, China, 201114
Public contact	GCR, Evive Biotechnology (Shanghai) Ltd, pr@evivebiotech.com
Scientific contact	GCR, Evive Biotechnology (Shanghai) Ltd, pr@evivebiotech.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	18 December 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	05 March 2020
Global end of trial reached?	Yes
Global end of trial date	18 March 2020
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study was to evaluate the efficacy of F-627 given as a single fixed dose (20 mg) pre-filled syringe as compared to Neulasta® standard dosing (6 mg) in the first chemotherapy cycle.

Protection of trial subjects:

This study was conducted in accordance with ICH GCP regulations/guidelines. The protocol, informed consent form and other subject information were approved by the Independent Ethics Committee / Institutional Review Board.

Background therapy:

75 mg/m<sup>2</sup> docetaxel + 600 mg/m<sup>2</sup> cyclophosphamide

Evidence for comparator:

Neulasta® standard dosing (6 mg)

Actual start date of recruitment	12 April 2018
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	6 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Russian Federation: 145
Country: Number of subjects enrolled	Ukraine: 166
Country: Number of subjects enrolled	United States: 1
Country: Number of subjects enrolled	Bulgaria: 36
Country: Number of subjects enrolled	Hungary: 45
Worldwide total number of subjects	393
EEA total number of subjects	81

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	332
From 65 to 84 years	61
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

This study was conducted between 12 Apr 2018 and 05 Mar 2020 at 41 study sites across five countries, including Bulgaria, Hungary, Russia, Ukraine, and the United States.

### Pre-assignment

Screening details:

A total of 416 subjects were screened and 393 were randomized to the study (197 randomized to F-627 and 196 randomized to Neulasta®). Overall, 373 (94.9%) subjects completed the treatment program, and 363 subjects (92.4%) who completed the 6 month follow-up.

### Period 1

Period 1 title	Period 1 (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	F-627
------------------	-------

Arm description:

F-627, 20mg fixed dose prefilled syringe, dosed on Day 2 of each of 4 chemotherapy cycles

Arm type	Experimental
Investigational medicinal product name	efbemalenograstim alfa
Investigational medicinal product code	L03AA18
Other name	Ryzneuta, F-627
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Solution for injection , Subcutaneous use

Dosage and administration details:

F-627, prefilled syringe administered on Day 2 of each of the 4 chemotherapy cycles

<b>Arm title</b>	Neulasta
------------------	----------

Arm description:

Neulasta, 6mg fixed dose prefilled syringe, dosed on Day 2 of each of the 4 chemotherapy cycles

Arm type	Active comparator
Investigational medicinal product name	Neulasta (pegfilgrastim)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use, Solution for injection

Dosage and administration details:

Neulasta, 6mg fixed dose prefilled syringe, dosed by subcutaneous injection on Day 2 of each of the 4 chemotherapy cycles

<b>Number of subjects in period 1</b>	F-627	Neulasta
Started	197	196
Completed	186	187
Not completed	11	9
Adverse event, serious fatal	1	-
Consent withdrawn by subject	2	1
Physician decision	2	2
Adverse event, non-fatal	5	5
Protocol deviation	1	1

## Baseline characteristics

### Reporting groups

Reporting group title	F-627
Reporting group description: F-627, 20mg fixed dose prefilled syringe, dosed on Day 2 of each of 4 chemotherapy cycles	
Reporting group title	Neulasta
Reporting group description: Neulasta, 6mg fixed dose prefilled syringe, dosed on Day 2 of each of the 4 chemotherapy cycles	

Reporting group values	F-627	Neulasta	Total
Number of subjects	197	196	393
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	171	161	332
From 65-84 years	26	35	61
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	51.4	53.4	-
standard deviation	± 11.82	± 11.11	-
Gender categorical			
Units: Subjects			
Female	197	196	393
Male	0	0	0
Race			
Units: Subjects			
White	197	196	393
Black or African American	0	0	0
Asian	0	0	0
American Indian or Alaska Native	0	0	0
Native Hawaiian or other Pacific Islander	0	0	0
Other	0	0	0
Reproductive Status			
Units: Subjects			
Childbearing potential	86	70	156
Post-menopausal	100	116	216
Surgically sterile	11	10	21
Baseline ECOG performance Status			
Units: Subjects			
ECOG 0	153	146	299

EOCG 1	44	50	94
EOCG 2	0	0	0
EOCG 3	0	0	0
EOCG 4	0	0	0
EOCG 5	0	0	0
Weight Units: Kg			
arithmetic mean	75.84	74.93	
standard deviation	± 16.88	± 16.87	-
BMI Units: Weight(kg) / [Height(m)^2]			
arithmetic mean	28.72	28.51	
standard deviation	± 6.36	± 6.20	-
Height Units: cm			
arithmetic mean	162.6	162.2	
standard deviation	± 6.27	± 6.67	-
BSA Units: [Height(cm) X Weight(kg)] / 3600]^1/2			
arithmetic mean	1.84	1.83	
standard deviation	± 0.21	± 0.21	-

### Subject analysis sets

Subject analysis set title	ITT
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
Intent-to-treat analysis set (ITT) included all randomized subjects	

Reporting group values	ITT		
Number of subjects	393		
Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	332		
From 65-84 years	61		
85 years and over	0		
Age continuous Units: years			
arithmetic mean	52.4		
standard deviation	± 11.50		
Gender categorical Units: Subjects			
Female	393		

Male	0		
------	---	--	--

Race			
Units: Subjects			
White	393		
Black or African American	0		
Asian	0		
American Indian or Alaska Native	0		
Native Hawaiian or other Pacific Islander	0		
Other	0		
Reproductive Status			
Units: Subjects			
Childbearing potential	156		
Post-menopausal	216		
Surgically sterile	21		
Baseline ECOG performance Status			
Units: Subjects			
ECOG 0	299		
ECOG 1	94		
ECOG 2	0		
ECOG 3	0		
ECOG 4	0		
ECOG 5	0		
Weight			
Units: Kg			
arithmetic mean	75.39		
standard deviation	± 16.86		
BMI			
Units: Weight(kg) / [Height(m)^2]			
arithmetic mean	28.62		
standard deviation	± 6.27		
Height			
Units: cm			
arithmetic mean	162.4		
standard deviation	± 6.47		
BSA			
Units: [Height(cm) X Weight(kg)] / 3600]^1/2			
arithmetic mean	1.83		
standard deviation	± 0.21		

## End points

### End points reporting groups

Reporting group title	F-627
Reporting group description:	F-627, 20mg fixed dose prefilled syringe, dosed on Day 2 of each of 4 chemotherapy cycles
Reporting group title	Neulasta
Reporting group description:	Neulasta, 6mg fixed dose prefilled syringe, dosed on Day 2 of each of the 4 chemotherapy cycles
Subject analysis set title	ITT
Subject analysis set type	Intention-to-treat
Subject analysis set description:	Intention-to-treat analysis set (ITT) included all randomized subjects

### Primary: Duration of severe neutropenia (DSN) in Cycle 1

End point title	Duration of severe neutropenia (DSN) in Cycle 1
End point description:	
End point type	Primary
End point timeframe:	Chemotherapy cycle 1

End point values	F-627	Neulasta		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	197	196		
Units: days				
arithmetic mean (standard deviation)	0.2 ( $\pm$ 0.51)	0.2 ( $\pm$ 0.45)		

### Statistical analyses

Statistical analysis title	FAS
Comparison groups	F-627 v Neulasta
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.7074 <sup>[1]</sup>
Method	t-test, 2-sided

Notes:

[1] - p-value was for the testing of mean (F-627) = mean (Neulasta®)

### Secondary: Number of Days of Intravenous Antibiotic Use

End point title	Number of Days of Intravenous Antibiotic Use
End point description:	

End point type	Secondary
End point timeframe:	
Across all 4 chemotherapy cycles	

<b>End point values</b>	F-627	Neulasta	ITT	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	197	196	393	
Units: Days				
arithmetic mean (standard deviation)	0.3 (± 1.36)	0.1 (± 0.70)	0.2 (± 1.09)	

### Statistical analyses

<b>Statistical analysis title</b>	FAS
Comparison groups	F-627 v Neulasta
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0538 [2]
Method	Wilcoxon (Mann-Whitney)

Notes:

[2] - p-value was based on the two-sided exact test from a Wilcoxon Rank Sum test

### Secondary: Number of Days of Hospitalization for Infection

End point title	Number of Days of Hospitalization for Infection
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Across all 4 chemotherapy cycles

<b>End point values</b>	F-627	Neulasta	ITT	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	197	196	393	
Units: Days				
arithmetic mean (standard deviation)	0.1 (± 0.78)	0.0 (± 0.57)	0.0 (± 0.69)	

### Statistical analyses

<b>Statistical analysis title</b>	FAS
Comparison groups	F-627 v Neulasta

Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 1 [3]
Method	Wilcoxon (Mann-Whitney)

Notes:

[3] - p-value was based on the two-sided exact test from a Wilcoxon Rank Sum test

### Secondary: Incidence of Febrile Neutropenia

End point title	Incidence of Febrile Neutropenia
-----------------	----------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Across all 4 chemotherapy cycles

End point values	F-627	Neulasta	ITT	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	197	196	393	
Units: event	6	1	7	

### Statistical analyses

<b>Statistical analysis title</b>	FAS
Comparison groups	F-627 v Neulasta
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1217 [4]
Method	Fisher exact

Notes:

[4] - p-value was for the proportion difference between F-627 and Neulasta® using Fisher's Exact Test

### Secondary: Incidence of Severe Neutropenia for Chemotherapy Cycle 1

End point title	Incidence of Severe Neutropenia for Chemotherapy Cycle 1
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Chemotherapy cycle 1

<b>End point values</b>	F-627	Neulasta	ITT	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	197	196	393	
Units: event	23	23	46	

### Statistical analyses

<b>Statistical analysis title</b>	FAS
Comparison groups	F-627 v Neulasta
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9853 <sup>[5]</sup>
Method	Chi-squared

Notes:

[5] - p-value was for the proportion difference between F-627 and Neulasta® using Chi-Square Test

### Secondary: Incidence of Use of Intravenous Antibiotics

End point title	Incidence of Use of Intravenous Antibiotics
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Across all 4 chemotherapy cycles

<b>End point values</b>	F-627	Neulasta	ITT	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	197	196	393	
Units: event	9	2	11	

### Statistical analyses

<b>Statistical analysis title</b>	FAS
Comparison groups	F-627 v Neulasta
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0618 <sup>[6]</sup>
Method	Fisher exact

Notes:

[6] - p-value was for the proportion difference between F-627 and Neulasta® using Fisher's Exact Test

**Secondary: Incidence of Hospitalization for Infection**

End point title	Incidence of Hospitalization for Infection
End point description:	
End point type	Secondary
End point timeframe:	
Across all 4 chemotherapy cycles	

End point values	F-627	Neulasta	ITT	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	197	196	393	
Units: event	1	1	2	

**Statistical analyses**

<b>Statistical analysis title</b>	FAS
Comparison groups	F-627 v Neulasta
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 1 [7]
Method	Fisher exact

Notes:

[7] - p-value was for the proportion difference between F-627 and Neulasta® using Fisher's Exact Test

**Other pre-specified: Incidence of Severe Neutropenia in Cycle 3**

End point title	Incidence of Severe Neutropenia in Cycle 3
End point description:	
End point type	Other pre-specified
End point timeframe:	
Chemotherapy Cycle 3	

End point values	F-627	Neulasta	ITT	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	193	191	384	
Units: Event				
Severe Neutropenia	5	12	17	

## Statistical analyses

No statistical analyses for this end point

### Other pre-specified: Incidence of Severe Neutropenia in Cycle 4

End point title Incidence of Severe Neutropenia in Cycle 4

End point description:

End point type Other pre-specified

End point timeframe:

Cycle 4

End point values	F-627	Neulasta	ITT	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	186	188	374	
Units: event				
Severe Neutropenia	3	10	13	

## Statistical analyses

No statistical analyses for this end point

### Other pre-specified: Incidence of Severe Neutropenia in Cycle 2

End point title Incidence of Severe Neutropenia in Cycle 2

End point description:

End point type Other pre-specified

End point timeframe:

Cycle 2

End point values	F-627	Neulasta	ITT	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	194	196	390	
Units: event				
Severe Neutropenia	9	10	19	

## Statistical analyses

No statistical analyses for this end point

---

**Post-hoc: Incidence of Protocol-defined Febrile Neutropenia**

---

End point title	Incidence of Protocol-defined Febrile Neutropenia
-----------------	---

End point description:

End point type	Post-hoc
----------------	----------

End point timeframe:

All cycles

---

<b>End point values</b>	F-627	Neulasta	ITT	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	197	196	393	
Units: events				
Febrile Neutropenia	3	1	4	

---

**Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Approximately 12 weeks (4 treatment cycles)

Adverse event reporting additional description:

All subjects who received at least 1 dose of F-627 or Neulasta were included in the safety analysis set.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.1
--------------------	------

### Reporting groups

Reporting group title	F-627
-----------------------	-------

Reporting group description:

F-627, 20mg fixed dose prefilled syringe, dosed on Day 2 of each of 4 chemotherapy cycles

Reporting group title	Neulasta
-----------------------	----------

Reporting group description:

Neulasta, 6mg fixed dose prefilled syringe, dosed on Day 2 of each of the 4 chemotherapy cycles

<b>Serious adverse events</b>	F-627	Neulasta	
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 197 (6.09%)	5 / 196 (2.55%)	
number of deaths (all causes)	1	2	
number of deaths resulting from adverse events	1	0	
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 197 (0.51%)	0 / 196 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Myocardial infarction			
subjects affected / exposed	0 / 197 (0.00%)	1 / 196 (0.51%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Syncope			
subjects affected / exposed	1 / 197 (0.51%)	0 / 196 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	2 / 197 (1.02%)	0 / 196 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anemia			
subjects affected / exposed	0 / 197 (0.00%)	1 / 196 (0.51%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	0 / 197 (0.00%)	1 / 196 (0.51%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 197 (0.51%)	0 / 196 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Hepatitis toxic			
subjects affected / exposed	0 / 197 (0.00%)	1 / 196 (0.51%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	1 / 197 (0.51%)	0 / 196 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	1 / 197 (0.51%)	0 / 196 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urticaria			

subjects affected / exposed	1 / 197 (0.51%)	0 / 196 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Renal and urinary disorders</b>			
Acute kidney injury			
subjects affected / exposed	1 / 197 (0.51%)	0 / 196 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			
Pneumonia			
subjects affected / exposed	2 / 197 (1.02%)	1 / 196 (0.51%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Metabolism and nutrition disorders</b>			
Diabetic ketoacidosis			
subjects affected / exposed	1 / 197 (0.51%)	0 / 196 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	F-627	Neulasta	
<b>Total subjects affected by non-serious adverse events</b>			
subjects affected / exposed	178 / 197 (90.36%)	169 / 196 (86.22%)	
<b>Investigations</b>			
Alanine aminotransferase increased			
subjects affected / exposed	19 / 197 (9.64%)	13 / 196 (6.63%)	
occurrences (all)	22	13	
Neutrophil count decreased			
subjects affected / exposed	15 / 197 (7.61%)	6 / 196 (3.06%)	
occurrences (all)	23	9	
Aspartate aminotransferase increased			
subjects affected / exposed	11 / 197 (5.58%)	10 / 196 (5.10%)	
occurrences (all)	14	10	
<b>Nervous system disorders</b>			

Headache subjects affected / exposed occurrences (all)	18 / 197 (9.14%) 23	10 / 196 (5.10%) 12	
Blood and lymphatic system disorders			
Neutropenia subjects affected / exposed occurrences (all)	40 / 197 (20.30%) 87	50 / 196 (25.51%) 110	
Anaemia subjects affected / exposed occurrences (all)	47 / 197 (23.86%) 75	38 / 196 (19.39%) 73	
Leukopenia subjects affected / exposed occurrences (all)	39 / 197 (19.80%) 98	44 / 196 (22.45%) 104	
Thrombocytopenia subjects affected / exposed occurrences (all)	20 / 197 (10.15%) 39	20 / 196 (10.20%) 39	
Leukocytosis subjects affected / exposed occurrences (all)	14 / 197 (7.11%) 59	10 / 196 (5.10%) 41	
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	58 / 197 (29.44%) 153	46 / 196 (23.47%) 132	
Fatigue subjects affected / exposed occurrences (all)	24 / 197 (12.18%) 53	17 / 196 (8.67%) 28	
Pyrexia subjects affected / exposed occurrences (all)	18 / 197 (9.14%) 25	9 / 196 (4.59%) 14	
Gastrointestinal disorders			
Nausea subjects affected / exposed occurrences (all)	71 / 197 (36.04%) 143	58 / 196 (29.59%) 115	
Diarrhoea subjects affected / exposed occurrences (all)	32 / 197 (16.24%) 48	27 / 196 (13.78%) 37	

Stomatitis subjects affected / exposed occurrences (all)	13 / 197 (6.60%) 26	12 / 196 (6.12%) 23	
Vomiting subjects affected / exposed occurrences (all)	12 / 197 (6.09%) 14	7 / 196 (3.57%) 10	
Skin and subcutaneous tissue disorders			
Alopecia subjects affected / exposed occurrences (all)	103 / 197 (52.28%) 108	100 / 196 (51.02%) 101	
Erythema subjects affected / exposed occurrences (all)	17 / 197 (8.63%) 35	17 / 196 (8.67%) 40	
Musculoskeletal and connective tissue disorders			
Bone pain subjects affected / exposed occurrences (all)	41 / 197 (20.81%) 77	34 / 196 (17.35%) 63	
Arthralgia subjects affected / exposed occurrences (all)	30 / 197 (15.23%) 70	22 / 196 (11.22%) 46	
Myalgia subjects affected / exposed occurrences (all)	21 / 197 (10.66%) 31	18 / 196 (9.18%) 29	
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	11 / 197 (5.58%) 13	7 / 196 (3.57%) 11	

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported